Risk of residual neoplasia after a noncurative colorectal endoscopic submucosal dissection for malignant lesions: a multinational study.


Journal

Endoscopy
ISSN: 1438-8812
Titre abrégé: Endoscopy
Pays: Germany
ID NLM: 0215166

Informations de publication

Date de publication:
03 2023
Historique:
pubmed: 22 7 2022
medline: 3 3 2023
entrez: 21 7 2022
Statut: ppublish

Résumé

BACKGROUND : Endoscopic submucosal dissection (ESD) in colorectal lesions is technically demanding and a significant rate of noncurative procedures is expected. We aimed to assess the rate of residual lesions after a noncurative ESD for colorectal cancer (CRC) and to establish predictive scores to be applied in the clinical setting. METHODS : Retrospective multicenter analysis of consecutive colorectal ESDs. Patients with noncurative ESDs performed for the treatment of CRC lesions submitted to complementary surgery or with at least one follow-up endoscopy were included. RESULTS : From 2255 colorectal ESDs, 381 (17 %) were noncurative, and 135 of these were performed in CRC lesions. A residual lesion was observed in 24 patients (18 %). Surgery was performed in 96 patients and 76 (79 %) had no residual lesion in the colorectal wall or in the lymph nodes. The residual lesion rate for sm1 cancers was 0 %, and for > sm1 cancers was also 0 % if no other risk factors were present. Independent risk factors for lymph node metastasis were poor differentiation and lymphatic permeation (NC-Lymph score). Risk factors for the presence of a residual lesion in the wall were piecemeal resection, poor differentiation, and positive/indeterminate vertical margin (NC-Wall score). CONCLUSIONS : Lymphatic permeation or poor differentiation warrant surgery owing to their high risk of lymph node metastasis, mainly in > sm1 cancers. In the remaining cases, en bloc and R0 resections resulted in a low risk of residual lesions in the wall. Our scores can be a useful tool for the management of patients who undergo noncurative colorectal ESDs.

Identifiants

pubmed: 35863354
doi: 10.1055/a-1906-8000
doi:

Banques de données

ClinicalTrials.gov
['NCT04484311']

Types de publication

Multicenter Study Clinical Trial Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

235-244

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

Thieme. All rights reserved.

Déclaration de conflit d'intérêts

The authors declare that they have no conflict of interest.

Auteurs

João Santos-Antunes (J)

Gastroenterology Department, Faculty of Medicine, Centro Hospitalar Universitário S. João, Porto, Portugal.
Ipatimup/i3S (Instituto de Investigação e Inovação em Saúde da Universidade do Porto), Porto, Portugal.

Mathieu Pioche (M)

Department of Hepatology and Gastroenterology, Edouard Herriot Hospital, Lyon, France.

Felipe Ramos-Zabala (F)

Department of Gastroenterology, Department of Clinical Medical Sciences, Hospital Universitario HM Montepríncipe, HM Hospitales, Universidad San Pablo-CEU, CEU Universities Madrid, Madrid, Spain.

Paolo Cecinato (P)

Gastroenterology and Digestive Endoscopy Unit, Azienda USL - IRCCS di Reggio Emilia, Reggio Emilia, Italy.

Francisco J Gallego Rojo (FJ)

Gastroenterology Department, Hospital de Poniente, Almería, Spain.

Pedro Barreiro (P)

Gastroenterology Department, Centro Hospitalar Lisboa Ocidental EPE, Lisbon, Portugal.
Lisbon Advanced Endoscopic Center, Hospital Lusíadas, Lisbon, Portugal.

Catarina Félix (C)

Gastroenterology Department, Centro Hospitalar Lisboa Ocidental EPE, Lisbon, Portugal.

Sandro Sferrazza (S)

Gastroenterology and Endoscopy Unit, Santa Chiara Hospital, Trento, Italy.

Frieder Berr (F)

Department of Internal Medicine I, University Clinics Salzburg, Paracelsus Medical University, Salzburg, Austria.

Andrej Wagner (A)

Department of Internal Medicine I, University Clinics Salzburg, Paracelsus Medical University, Salzburg, Austria.

Arnaud Lemmers (A)

Department of Gastroenterology, Hepatopancreatology and Digestive Oncology, CUB Erasme Hospital, Université Libre de Bruxelles (ULB), Brussels, Belgium.

Mariana Figueiredo Ferreira (M)

Department of Gastroenterology, Hepatopancreatology and Digestive Oncology, CUB Erasme Hospital, Université Libre de Bruxelles (ULB), Brussels, Belgium.

Eduardo Albéniz (E)

Navarrabiomed Research Institute, Complejo Hospitalario de Navarra, Public University of Navarra, IdiSNA, Pamplona, Spain.

Hugo Uchima (H)

Digestive Endoscopy Service, Centro Médico Teknon, Barcelona, Spain.
Gastroenterology Service, Hospital Universitario Germans Trias i Pujol, Barcelona, Spain.

Ricardo Küttner-Magalhães (R)

Gastroenterology Department, Hospital Santo António, Centro Hospitalar Universitário do Porto, Porto, Portugal.

Carlos Fernandes (C)

Gastroenterology Department, Centro Hospitalar de Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal.

Rui Morais (R)

Gastroenterology Department, Faculty of Medicine, Centro Hospitalar Universitário S. João, Porto, Portugal.

Sunil Gupta (S)

Department of Gastroenterology and Hepatology, Westmead Hospital, Sydney, Australia.

Daniel Martinho-Dias (D)

Department of Community Medicine, Information and Decision in Health, Faculty of Medicine, University of Porto, Porto, Portugal.

Elisabete Rios (E)

Pathology Department, Faculty of Medicine, Centro Hospitalar Universitário S. João, Porto, Portugal.

Isabel Faria-Ramos (I)

Ipatimup/i3S (Instituto de Investigação e Inovação em Saúde da Universidade do Porto), Porto, Portugal.

Margarida Marques (M)

Gastroenterology Department, Faculty of Medicine, Centro Hospitalar Universitário S. João, Porto, Portugal.

Michael J Bourke (MJ)

Department of Gastroenterology and Hepatology, Westmead Hospital, Sydney, Australia.

Guilherme Macedo (G)

Gastroenterology Department, Faculty of Medicine, Centro Hospitalar Universitário S. João, Porto, Portugal.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH